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Summary: Antibodies were raised against seven major matrix metalloproteinases: stromelysin-1 (MMP-3), strome-
lysin-2 (MMP-10), stromelysin-3 (MMP-11), interstitial collagenase (MMP-1), M. 72 000 type IV collagenase
(72 kDa type IV collagenase, MMP-2), MT 92 000 type IV collagenase (92 kDa type IV collagenase, MMP-9) and
matrilysin (PUMP, MMP-7) as well as against prolyl 4-hydroxylase, to study the expression of these collagenolytic
enzymes in normal liver in relation to the activity of collagen synthesis. Tissue samples of four normal human
livers, three hepatocellular carcinomas and one cholangiocellular carcinoma were analysed. In normal liver we
found expression of stromelysin-1, stromelysin-3, interstitial collagenase, MT 72 000 and Mr 92 000 type IV collagen-
ases and varying expression of prolyl 4-hydroxylase. Stromelysin-2 was inconsistently detectable; matrilysin was
not found. In hepatocellular carcinoma the expression pattern of matrix metalloproteinases showed only minor
changes compared with the normal tissue; stronger signals than in normal tissue were seen for stromelysin-1, and
stromelysin-2 was also strongly positive. 72 000 and MT 92 000 type IV collagenases and interstitial collagenase
were less strongly expressed; stromelysin-3 was unchanged. Expression of prolyl 4-hydroxylase was also increased
compared with normal liver. Matrilysin was only seen in cholangiocellular carcinoma, which showed a completely
different pattern of matrix metalloproteinase expression.
Our results show that metalloproteinases are expressed in human liver with much greater abundance than previously
described. Their expression pattern is not changed fundamentally in hepatocellular carcinoma but is completely
different from that of other tumour tissues such as cholangiocellular carcinoma.
Introduction breakdown and matrix turnover in normal and diseased
liver is still poorly understood.
The normal liver matrix contains about 4—6 mg colla-
gen per gram liver tissue. In fibrotic diseases the colla- Circumstantial evidence suggests that in normal liver
gen content is significantly increased, reaching as much collagen synthesis and turnover are balanced, keeping
as 30% of the total liver weight (1). Extracellular matrix the collagen content fairly stable (4). In chronic diseases
consists of different collagens, of which collagen type this balance might be tilted towards an increasing predo-
I is the most abundant, comprising up to 70% of the minance of fibrogenesis, resulting in an accumulation of
extracellular matrix in fibrotic liver. collagenous matrix and finally organ fibrosis and cirrho-
sis.
While considerable progress has been made concerning
the cellular source of matrix proteins (collagens, glycos- Collagen turnover is largely the effect of matrix metallo-
aminoglycans and glycoproteins) and the regulation of proteinases, a family of neutral proteinases requiring
their expression (2, 3), the amount and rate of collagen zinc ions for activity and digesting different collagens
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and gelatins (denatured collagen derivatives) (5, 6).
Their activity is regulated both on the transcriptional
level, by proenzyme activation and finally by inhibitors
which are coexpressed and are present at the tissue sites
of enzyme activity (7). Earlier reports suggest that he-
patic perisinusoidal (Ito-) cells, besides producing dif-
ferent collagens are also capable of expressing matrix
metalloproteinases (8-10). High levels of collagenase
activity have been found in alcoholic liver disease with
active fibrogenesis and after carbon tetrachloride poi-
soning in the rat. It is not known however, which of the
numerous collagenases were responsible for this effect
(11, 12).
Other investigators found Mr 72 000 type IV collagenase
(MMP-2) transcripts in normal and both interstitial col-
lagenase (MMP-1) and Mr 72000 type IV collagenase
transcripts in fibrotic human liver (13). Very little is
known about the expression of other matrix metallopro-
teinases or their inhibitors in the human liver in vivo
(14).
In the study presented here, we investigated the expres-
sion of seven major matrix metalloproteinases and of
prolyl 4-hydroxylase, the rate limiting enzyme of post-
translational modification of collagen, in normal human
liver and in hepatocellular as well as cholangiocellular
tumour tissue. The aim of the study was to establish
laboratory methods for further studies of metalloprotein-
ase expression and to determine which metalloprotein-
ase repertoire is found in normal liver.
Materials and Methods
Production of specific antisera against different matrix
metal loproteinases and prolyl 4-hydroxylase
Fragments of cDNA, coding for parts of the haemopexin-like do-
main (15) of stromelysin-11), stromelysin-21), stromelysin-31), Mr
72000 type IV collagenase1), MT 92000 type IV collagenase1), in-
terstitial collagenase1), for part of the propeptide- and catalytic do-
main of matrilysin1) and the carboxy-terminus of the α-subunit of
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EcoR.1: Restriction endonuclease from Escherichia coli
Hind\\\: Restriction endonuclease from Haemophilus influenzae
Rd
BamHl: Restriction endonuclease from Bacillus amyloliquefa-
ciens H
Xba\: Restriction endonuclease from Xanthomonas campestris
pv. badrii
tors pGEX-2T (16), pET-21a(+) (17) and pUR-288 (18) as fol-
lows.
cDNA sequences coding for weakly conserved domains of the pro-
teins were amplified by polymerase chain reaction (PCR) as de-
scribed by Saiki et al. (19) using the following oligonucleotide
primers:
Stromelysin-1 (MMP-3)
STR1: 5TAT GGA TCC CCC CCT GAC TCC CCT GAG3'
5'ATG GAA TTC AGO TTC AAG CTT CCT GAG G3'
STROM: 5'CTG GGA TCC GAC ACT CTG GAG GTG ATG C3'
5lCGA GAA TTC AAT TGG TCC CTG TTG TAT CC3f
Stromelysin-2 (MMP-10)
STR2: 5TAC GGA TCC CCC CCT GCC TCT ACT GAG G3'
5tATG GAA TTC AGG TTC AGG GTT CCA GTG G3'
Stromelysin-3 (MMP-11)
STR3: 5lACA GGA TCC AAG GCC CTG ATG TCC GCC
TTC3,
5'CTC GAA TTC AGC GTC CAC AGG GCT GGG C3?
Matrilysin (MMP-7)
PU: 5'CCT GGA TCC CTG GCC CTG CCG CTG CCT3'
51 AAT GAA TTC ATG TTC TGC CTG AAG TTT C3'
MT 72000 type IV collagenase (MMP-2)
72 KD: 5lCGT GGA TCC TAT GGG GCC TCT CCT G3'
5lGCG GAA TTC ACT CGC TGG ACA TCA GGG3'
Mr 92 000 type IV collagenase (MMP-9)
92 KD: 5lCGT GGA TCC GAC GAC GTG AAT GGC A3'
5TGC GAA TTC ACG TCG AAC CTC CAG AGG3'
Interstitial collagenase (MMP-1)
1C: 5lGAT GGA TCC CAA GCC ATA TAT GGA CGT
TCC3'
5lTTG GAA TTC CGG ACT TCA TCT CTG TCG G3'
Prolyl 4-hydroxylase (a-subunit)
PH: 5'AAG GGA TCC TGG CTC TCT GGC TAT GA3'
5'ATC GAA TTC TCC ACT GGC AAA CAG A3'
The denaturing temperature was 94 °C, annealing temperatures
were 54—59 °C. Thirty-five cycles at 72 °C were run using first
strand cDNA matrices (0.2 μg) derived from human breast carci-
noma (for stromelysin-1,-2,-3) or a liver metastasis of a colon car-
cinoma (for matrilysin, Mr 72 000 and Mr 92 000 type IV collagen-
ases, interstitial collagenase and prolyl 4-hydroxylase), respec-
tively. For cloning purposes, BamHl recognition sites were in-
cluded in the sense and EcoRl recognition sites in the antisense
























































were digested with restriction enzymes BamHl1) and EcoRl1) and
then ligated with BamHl/EcoRl cut pGEX-2T-DNA yielding
STR1-, STR2-, STR3-, PU-, 1C-, 72KD-, 92KD- and PH-pGEX
expression clones, respectively. Sequences were similary cloned
into the expression vector pET-2la(+) using DNA fragments am-
plified by PCR with primer pairs as above except that EcoRl re-
cognition sites were substituted by HindllV) sites. When using the
pUR-288 expression vector, EcoRl sites were substituted by Xbal1)
sites. Clones were checked by sequencing (28).
Expression of the fusion proteins was induced with 0.5 mrnol/l
isopropyl -D-thiogalacto-pyranoside for pGEX (yielding a fusion
protein with MT 27 500 glutathione S-transferase at the amino-ter-
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minus), pET-21a(+) constructs (giving a fusion protein with a 18
amino acids peptide, including a histidine-tag, at the carboxy-ter-
minus) and pUR-288 (amino-terminal fusion with MT 116000 of
-galactosidase). Cells were lysed by sonication three hours after
induction and centrifuged at 10000g. The pellets were resus-
pended in SDS sample buffer and subjected to preparative SDS
polyacrylamide gel electrophoresis; bands containing the induced
fusion proteins were excised and electroeluted using a Biotrap ap-
paratus (Schleicher & Sch ll, Germany). Purity of the recovered
proteins was assayed by analytical SDS polyacrylamide gel elec-
trophoresis. Protein concentrations were determined colorime-
trically with coomassie brilliant blue staining (29). The pGEX fu-
sion proteins were used to immunize 4- to 5-month old Chinchilla
rabbits following standard protocols (30). Specificities of the anti-
sera were determined by enzyme-linked immunosorbent-assay
(ELISA) (30) using either pGEX fusion proteins after affinity chro-
matography on glutathione-sepharose columns (Pharmacia) and
thrombin-cleavage (STR1, STR2) (16), pET constructs (STR3, PU,
1C and PH) or pUR fusion proteins (72 KD and 92 KD) as antigens
to avoid cross reactivities from the glutathione S-transferase part
of the fusion protein.
Sera were stored in aliquots at —20 °C until used. An additional
construct (STROM-pGEX) encompassing an amino-terminal por-
tion of stromelysin-1 (STROM: nucleotides 227—646, amino acids
72-210) was prepared like STRl-pGEX for characterizing spe-
cific antibodies against PUMP.
Enzyme-linked immunosorbent-assay (ELISA) (30)
Microtitre plates were coated overnight with 100 μΐ of the antigen
(1 mg/1) diluted in coating buffer (106 g/1 Na2CO3, 336 g/1
NaHCOs) and then blocked for 30 min in an additional 150 μΐ
blocking buffer (50 mmol/I NaH2PO4, 150 mmol/1 NaCI, 0.5 g/1
Tween 20, 0.2 g/1 NaN3, 1 g/1 haemoglobin; pH 7.2). The plates
were washed three times with 200 μΐ washing buffer (blocking
buffer without haemoglobin). Hundred μΐ of crude antisera diluted
in blocking buffer were incubated for two hours (dilutions are indi-
cated in the legend to fig. 1) then washed three times with 200 μΐ
phosphate-buffered saline before peroxidase conjugated sheep anti-
rabbit IgG antibody (1 : 500) (Boehringer Mannheim) was added.
After a 30 min incubation it was washed three times with phos-
phate-buffered saline. The antibody complex was visualized 10 min
after addition of the chromogen di-ammonium 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonate) (ABTS) (Boehringer Mann-
heim) giving raise to a green colour whose intensity was measured
at 405 mri.
Tissue preparation
Normal liver tissue was obtained from four explanted livers which
were meant for liver transplantation but could not be utilized for
reasons unrelated to this study. Tumour tissue was excised from
resected neoplasms immediately in the operation theatre and placed
in cold Ringer lactate solution (Baxter) on crushed ice. Three hepa-
tocellular carcinomas and one cholangiocellular carcinoma were
analysed. Pieces of approximately 100 mg were homogenized in
300 μΐ SDS sample buffer (125 mmol/1 Tris/HCl, pH 6.8, 30 g/1
sodium dodecylsulphate, 50 g/1 2-mercaptoethanol, 150 g/1 glyc-
erol) using an ultra-turrax (Kinematica). The samples were boiled
for 10 min, centrifuged at 10 000 g and the supernatant was stored
at -20 °C,
Western blot analysis
The tissue extracts (1 —4 μΐ, see tissue preparation) were subjected
to analytical SDS polyacrylamide gel electrophoresis (gel size: 6.0
X 8.5 cm) and then transferred to nitrocellulose strips (BA85,
Schleicher & Schuell) in a Sartoblot2 transfer appartus (Sartorius).
A set of prestained protein standards was simultaneously run on
SDS polyacrylamide gel electrophoresis and transferred to excised
strip. The blotted membrane was blocked over night with 1%
blocking reagent (Boehringer Mannheim) in Tris-buffered saline
(50 mmol/1 Tris base, 150 mmol/1 NaCI, pH 7.5). Subsequently,
membrane strips were incubated for two hours at room temperature
with the primary antiserum diluted in 5 g/1 blocking reagent in Tris-
buffered saline (dilutions are indicated in the legend to fig. 2).
Membrane, strips were washed two times in Tris-buffered saline
with 1 g/1 Tween 20, two times in 5 g/1 blocking reagent in Tris-
buffered saline, and incubated for a further hour with peroxidase-
conjugated sheep anti-rabbit IgG (Boehringer Mannheim; 1 : 1000
in 5 g/1 blocking reagent in Tris-buffered saline). After four wash-
ing steps in Tris-buffered saline (with 1 g/1 Tween 20) immunore-
active bands were visualized using a luminol-based detection sys-
tem (Boehringer Mannheim) and a i min exposure to X-OMAT
AR-film (Kodak). For competition analysis, diluted primary anti-
sera were preincubated with fusion proteins (10 mg/1) for twelve
hours, prior to incubation with the membrane strip.
Cell isolation
Ten day old cultures of hepatic cell preparations were analysed.
Cells were isolated by the two step collagenase method accord-
ing to Seglen (31). After isolation the entire cell-suspension,
containing hepatocytes and all non-parenchymal cell fractions
was cultured on collagen-coated plastic dishes in medium 199
earle (Seromed) supplemented with insulin, dexamethasone, peni-
cillin/streptomycin and 100 g/1 fetal calf serum. Cells were
seeded at a density of approximately 4 X 106 per 25 cm2 dish.
Medium was changed every 24 hours. Cells were harvested on
day ten by removing them from the culture dish with a rubber
policeman. They were washed three times with phosphate-buf-
fered saline, centrifuged at 10 000 g, homogenized and analysed
as described for tissue samples.
Results
Antibody engineering
Using published cDNA sequences of seven major matrix
metalloproteinases, we selected primers and amplified
cDNA sequences of these proteins from human tumour
tissues by the polymerase chain reaction (see Materials
and Methods). cDNA sequences were derived from parts
of the haemopexin-like domain of the matrix metallo-
proteinase gene family. In the case of matrilysin, where
this region is completely absent, we selected the propep-
tide and catalytic domain (15). The cDNA sequences
chosen show as little sequence homology to other mem-
bers of the matrix metalloproteinase family on the pro-
tein level as possible. The amplified cDNA fragments
were shown to be of the expected molecular size and
were sequenced and found to be identical to the pub-
lished cDNA sequences (20—27). They were cloned into
bacterial expression vectors in E. coli (see Materials and
Methods). Since the sequences chosen did not contain
glycosylation sites, the synthesized proteins could suc-
cessfully be used as antigenic substitutes in rabbits, in-
ducing antibodies which should specifically recognize a
single member of the matrix metalloproteinase family.
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Specificity of the raised antisera
Figure 1 shows the results of ELISA-testing of crude
rabbit-antisera against their own and related recombi-
nant antigens. Comparisons between STR1-, STR2-,
STR3-, 1C-, 72 KD- and 92 KD-antigens were per-
formed with each antisera. For testing anti-PU (anti-mat-
rilysin) we used a recombinant stromelysin-1 (STROM)
which corresponds to the homologous region of the mat-
rilysin-antigen (see Materials and Methods). All the anti-
sera recognized their respective recombinant antigens
with sufficient specificity. Anti-STRl (anti-stromelysin-
1) cross reacted with both the stromelysin-1 and the stro-
melysin-2 antigen, while anti-STR2 (anti-stromelysin-2)
only showed a weak cross-reactivity with stromelysin-1.
Immunoblotting (western blots, see fig. 2) revealed that
the antisera also reacted with the intact human matrix
metalloproteinase proteins. The shown reference blots
3 4 5 6 3 4 5 6
Negative logarithm of antibody dilution
Fig. 1 Determination of the specificity of each antisemm against
recombinant protein fragments.





d) anti-72 KD (Mr 72000 type IV collagenase),
e) anti-92 KD (MT 92000 type IV collagenase),
f) anti-IC (interstitial collagenase),
g) anti-PU (matrilysin),
h) anti-PH (prolyl 4-hydroxylase, a-subunit).













(~O-) (see Materials and Methods).
Absorbances were measured at 405 nm and plotted against dilution
of antisera listed as negative logarithms.
demonstrate that dominant bands of the appropriate mo-
lecular size were detected by the antisera in preparations
derived from cultures of human liver cells, tumour tissue
and serum.
Each antiserum detected a band of f the molecular size
reported in the literature for the proenzyme form of the
individual matrix metalloproteinase. Other bands also
visible were not competitively inhibitable (data not
shown), but in no case showed comparable intensities to
the dominant ones.
Anti-STRl (anti-stromelysin-1) and anti-STR3 (anti-
stromelysin-3) recognized bands comigrating with the
MT 67 000 marker band, anti-IC (anti-interstitial colla-
genase) and anti-STR2 (anti-stromelysin-2) reacted with
a band above the Mr 50 000 marker band, anti-72 KD
(anti-Mr 72 000 type IV collagenase) recognized a band
of approximately Mr 72000, and anti-92 KD (anti-Mr
92000 type IV collagenase) recognized a band above
the MT 89000 marker band. Anti-PU (anti-matrilysin)
reacted with a band comigrating with the smallest
marker band of Mr 34 000; the band detected by anti-PH
(anti-prolyl 4-hydroxylase) was just smaller than the Mr
67 000 marker band.
Expression of matrix metalloproteinases
We used our antisera to detect matrix metalloproteinases
in normal human liver and in hepatic tumours. Figure 3
shows the results of western blots done with homoge-
nized liver or tumour tissue.
In normal human liver we found stromelysin-1 and -3,
interstitial collagenase, both type IV collagenases (Mr
72000 and Mr 92000) and differing quantities of prolyl
4-hydroxylase. Stromelysin-2 was only inconsistently
detectable and showed very weak bands, and matrilysin
was not detectable. Stromelysin-1 and Mr 72000 type
IV collagenase seemed to be the most abundant of the
matrix metalloproteinases in normal liver.
In the three hepatocellular carcinomas, the matrix metal-
loproteinase content seemed to be about the same as in
normal tissue, although the expression level did seem to
vary: most interestingly, stromelysin-2, hardly detectable
in normal liver, was strongly positive in two of three
hepatocellular carcinomas tested. Interstitial collagenase
and both Mr 72000 and 92000 type IV collagenases
were less strongly detectable in the tumours. Thus stro-
melysins seemed to be preg lated in the tumours, while
all the collagenases tested were not. ,?
Neither in normal liver nor in hepatocellular carcinoma
could we detect any matrilysin protein.
Prolyl 4-hydroxylase was also more strongly positive in
hepatocellular carcinoma than iri hormal liver.
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Fig. 2 Immunoblot determination of the specific recognition of
human matrix metalloproteinases and prolyl 4-hydroxylase by
newly raised antisera.
Crude cell-preparations of liver cells were separated by 9% SDS
polyacrylamide gel electrophoresis, immunoblotted using poly-
clonal
anti-STRl (anti-stromelysin-1, 1 : 2000, a);
anti-STR3 (anti-stromelysin-3, 1 : 1000, b);
anti-IC (anti-interstitial collagenase, 1 : 500, c);
anti-72 KD (anti-Mr 72 000 type IV collagenase, 1 : 2000, d);
anti-92 KD (anti-Jtfr 92000 type IV collagenase, 1 : 500, e);
anti-PH (anti-prolyl 4-hydroxylase, α-subunit, I : 1000, f);
anti-STR2 (anti-stromelysin-2, 1 : 1000, g);













antisera and visualized using a luminol-based detection system. For
controls antisera were blocked by preincubation with the corre-
sponding antigens always yielding blank strips, as shown here in
the case of anti-72 KD (i). Strong signals were detected with anti-
92 KD using human serum from a patient with posthepatic cirrho-
sis as shown in (k). The antibodies always recognized bands with
apparent molecular masses, which correlated well with published
data. Molecular mass markers were a set of prestained proteins
(prestained SDS-PAGE standard solution, (Sigma) with molecular
masses of native proteins [A/r, 103] of 27, 36, 45, 58, 84 and 116)
with apparent molecular masses [Λ/Γ, 103] of 34, 37, 50, 67, 89
and 123.
The one cholangiocellular carcinoma tested showed an
altogether different pattern of matrix metalloproteinases.
Interstitial collagenase and MT 92 000 type IV collagen-
ase were not detectable, while stromelysin-2 was less
intense than in the hepatocellular carcinomas. Stromely-
sin-1 and stromelysin-3 showed bands of smaller size in
the cholangiocellular carcinoma than in all other tissues
tested. Matrilysin was only detectable in the cholangio-
cellular carcinoma. Prolyl 4-hydroxylase was not found.
Discussion
Many authors believe that hepatic fibrosis and cirrhosis
occur in situations of a disturbed equilibrium between
collagen synthesis and degradation within the liver (4,
5). Following this hypothesis one would expect to find
both collagen synthesis as well as collagen degradation
in the normal liver. However, although this hypothesis
is not a new one (32) little is known about the expression
of collagenolytic enzymes in normal or diseased hu-
man liver.
Arthur and coworkers described synthesis and expres-
sion of type IV collagenase by rat and human lipocytes
(9, 10). This expression increased during the process of
lipocyte activation, which is thought to take place also
during the development of hepatic fibrosis (33). Milani
et al. demonstrated mRNA transcription for Mr 72 000
type IV collagenase in both normal and diseased human
liver by in situ hybridisation (13). They could not detect
any mRNA for interstitial collagenase, however, and did
not look for any other metalloproteinases. The main
source of the mRNA detected was mesenchymal cells,
thought to be perisinusoidal lipocytes.
In regenerating rat liver, Herbst et al. found increasing
levels of mRNA for transin/stromelysin in both hepato-
cytes (maximum 24 hours) and lobular mesenchymal
cells (maximum 48 hours) after carbon tetrachloride in-
jury (34).
In serum of patients with chronic liver diseases some
investigators found increased collagenase activity, while
others described profound reductions in serum collagen-
ase activity with development of chronic active hepatitis
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Fig. 3 Expression of different matrix metalloproteinases and pro-
lyl 4-hydroxylase in human liver and liver carcinomas.
Crude tissue preparations (see Materials and Methods) were sepa-
rately by 9% SDS polyacrylamide gel electrophoresis and immu-
noblotted using polyclonal antibodies against stromelysin-1, stro-
melysin-2, stromelysin-3, matrilysin, MT 72000 type IV collagen-
ase, MT 92 000 type IV collagenase, interstitial collagenase and pro-
lyl 4-hydroxylase (antibody dilutions see legend to fig. 2). Tissue
preparations were from
hepatocellular carcinoma (1-3);
cholangiocellular carcinoma (4) and
normal human liver (5-8).
Immunoreactive bands were visualized using a luminol-based de-
tection system. No bands of significance were observed in other
regions of the gels. For molecular mass markers see legend to fig-
ure 2.
(minus 50% compared with healthy subjects) and cirrho-
sis (minus 66%!) (35).
Thus the picture is far from clear. The aim of our own
study was, therefore, to describe the pattern of expres-
sion of metalloproteinases in normal human liver. He-
patic tumours were used for comparison, since we ex- Acknowledgement
pected to find higher expression of matrix metallopro-
teinases in malignant than in normal liver cells.
Using antibodies against recombinant proteins we were
able to show that stromelysin-1 and -3, interstitial colla-
genase, and both type IV collagenases (Mr 72 000 and
MT 92 000) are present in healthy human liver. We also
detected weak signals for stromelysin-2 in three of the
normal livers analysed. Only matrilysin was not detect-
able. Interestingly, with regard to the equilibrium hy-
pothesis, we also found varying degrees of prolyl 4-
hydroxylase expression in normal liver tissue, suggest-
ing that indeed some collagen synthesis takes place.
In the hepatocellular carcinomas we saw expression of
all the metalloproteiri ses tested for, except matrilysin.
Stromelysin-2 was also strongly positive in two of the
three hepatocellular carcinomas.
Mr 72000 type IV collagenase seemed to be less
strongly expressed in hepatocellular carcinoma than in
normal liver. This may be in accordance with the finding
by Murawaki (35) who described reduced levels of col-
lagenase activity in the serum of patients with hepatocel-
lular carcinoma. In the only cholangiocellular carcinoma
analysed, there was a completely different pattern of
metalloproteinase expression. It was the only tissue Jn
which we were able to detect matrilysin, and it appar-
ently synthesized different forms of stromelysin-1 and
stromelysin-3 from those in normal liver and the hepato-
cellular carcinomas. This seems entirely possible, since
different secreted proenzyme forms of stromelysin have
been described in other tissue (14, 36-38). Since matrix
metalloproteinases are present in tissues mainly in their
inactive pro-enzyme form, it is not surprising that our
antibodies mainly recognize bands of the molecular
mass of these proenzymes. In some of the gels more
than one band was identified^ suggesting that the anti-
bodies in our polyclonal antisera may recognize other
forms of the enzymes as well, such as pre-pro-enzyrnes,
degradation products with partly conserved structure or
even enzyme/inhibitor complexes. On the other hand,
bands of the size of the active forms were hardly de-
tected, suggesting that the concentration of active en-
zyme in the tissue is very low. Apparently there is a
certain redundancy in the expression of matrix metallo-
proteinases in the liver, in that almost the whole family
of these enzymes can be detected. The precise regulation
and cellular origin of these enzymes awaits further
study.
Our results are surprising in that they show a much more
abundant presence of matrix metalloproteinases in nor-
mal liver than hitherto described.
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